BCM
JNCE

BlueCrest Capital Management’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

BlueCrest Capital Management’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-12,488
Closed -$81K – 1532
2018
Q3 		$81K Buy
+12,488
New +$92.9K ﹤0.01% 1409

Other funds holding JNCE

TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

BlueCrest Capital Management's JNCE Position: Q4 2018 in Review

BlueCrest Capital Management sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q4 2018, closing a stake of 12,488 shares — an estimated $81K sold.

BlueCrest Capital Management first reported a position in JNCE in Q3 2018 and held it in 1 quarter. The position peaked at $81K in Q3 2018. 84 funds tracked by Wall St. Rank hold JNCE as of Q4 2018.

  • BlueCrest Capital Management reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • BlueCrest Capital Management sold 12,488 Jounce Therapeutics, Inc. Common Stock shares in Q4 2018, an estimated $81K.
  • BlueCrest Capital Management first reported a position in Jounce Therapeutics, Inc. Common Stock in Q3 2018 and held it in 1 quarter.
  • BlueCrest Capital Management's Jounce Therapeutics, Inc. Common Stock position peaked at $81K in Q3 2018.
  • 84 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q4 2018.

Based on BlueCrest Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.